- Kashiv BioSciences announced that Health Canada has validated and accepted the marketing authorization application for ADL-018, its proposed biosimilar to XOLAIR (omalizumab).
- Omalizumab is approved for several indications, including moderate-to-severe persistent asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and IgE-mediated food allergy.
- The regulatory acceptance represents an important step forward for Kashiv’s biosimilars pipeline, highlighting the company’s development and manufacturing capabilities as it progresses toward potential commercialization.
- If approved, ADL-018 could offer a more cost-effective treatment option in a market where XOLAIR generated approximately $135 million in annual Canadian sales during the 12 months ending June 2025.
Takeaways:
Kashiv BioSciences gets a key regulatory step for its XOLAIR (omalizumab) biosimilar, ADL-018.
The market implication is a likely cost-reduction play in a high-value omalizumab segment (~$135M in Canada). If approved, ADL-018 should pressure branded pricing, expand access across asthma, nasal polyps, chronic urticaria, and food allergy indications, and set up a payer-favored alternative for public and private drug plans.
Source: Businesswire
